Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Autologous CD19-directed CAR-T cells(University of Sao Paulo) in High grade B-cell lymphoma: NCT06101381 Clinical Landscape Report 2026
16 October 2026
NCT06101381 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Datopotamab Deruxtecan in PD-L1 positive Triple Negative Breast Cancer: NCT06103864 Clinical Landscape Report 2026
16 October 2026
NCT06103864 clinical landscape for PD-L1 positive Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Albumin-Bound Paclitaxel in Neoplasm Metastasis: NCT06107868 Clinical Landscape Report 2026
16 October 2026
NCT06107868 clinical landscape for Neoplasm Metastasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
WTX-613 in Hepatocellular Carcinoma: NCT06108050 Clinical Landscape Report 2026
16 October 2026
NCT06108050 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Surufatinib in Soft Tissue Sarcoma: NCT06110650 Clinical Landscape Report 2026
16 October 2026
NCT06110650 clinical landscape for Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Triple Negative Breast Cancer: NCT06112379 Clinical Landscape Report 2026
16 October 2026
NCT06112379 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Renal Cell Carcinoma: NCT06114940 Clinical Landscape Report 2026
16 October 2026
NCT06114940 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cadonilimab in Soft Tissue Sarcoma: NCT06114173 Clinical Landscape Report 2026
16 October 2026
NCT06114173 clinical landscape for Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Penpulimab in Osteosarcoma, Recurrent: NCT06114225 Clinical Landscape Report 2026
16 October 2026
NCT06114225 clinical landscape for Osteosarcoma, Recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Palbociclib in Sarcoma: NCT06113809 Clinical Landscape Report 2026
16 October 2026
NCT06113809 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gemcitabine Hydrochloride in Soft Tissue Sarcoma: NCT06114004 Clinical Landscape Report 2026
16 October 2026
NCT06114004 clinical landscape for Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SGN-35T in Hodgkin's Lymphoma: NCT06120504 Clinical Landscape Report 2026
16 October 2026
NCT06120504 clinical landscape for Hodgkin's Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.